{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-22-000089","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2022-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.645665+00:00","generated_at":"2026-06-25T00:00:50.413343+00:00","sec_items":["5.02","5.07","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BeiGene's NMPA accepts sBLA for tislelizumab in first-line PD-L1+ gastric cancer","bullets":["CDE of NMPA accepted sBLA for tislelizumab + chemo as first-line treatment for advanced G/GEJ adenocarcinoma with PD-L1 expression.","Submission supported by interim analysis of global Phase 3 RATIONALE 305 trial showing survival benefit.","This is the 10th regulatory submission for tislelizumab in China; it is already approved for 9 indications there.","Tislelizumab is also under FDA and EMA review for ESCC and NSCLC; partnered with Novartis in North America, Europe, Japan.","Gastric cancer is the 2nd leading cause of cancer death in China; few options exist for metastatic disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-22-000089","json":"https://secwatch.observer/filing/0001651308-22-000089.json","markdown":"https://secwatch.observer/filing/0001651308-22-000089.md","text":"https://secwatch.observer/filing/0001651308-22-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130822000089/0001651308-22-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130822000089/bgne-20220621.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T00:00:50.413343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4cb19816bf","claim":"Timothy Chen resigned as Director at BeOne Medicines Ltd..","evidence_excerpt":"On June 22, 2022, Timothy Chen resigned from the Board of Directors (the “Board”) of BeiGene, Ltd. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130822000089/0001651308-22-000089-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}